Evidence map›Paper›PMID 29942514›Full record

ReviewBiomarker research2018

microRNA based prognostic biomarkers in pancreatic Cancer.

Shixiang Guo, Andrew Fesler, Huaizhi Wang, Jingfang Ju

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shixiang Guo1Stony Brook University, Stony Brook, New York, 11794 USA.
Andrew Fesler1Stony Brook University, Stony Brook, New York, 11794 USA.
Huaizhi Wang2Third Military Medical University, Chongqing, 400038 People's Republic of China.
Jingfang Ju1Stony Brook University, Stony Brook, New York, 11794 USA.

Funding

Roles of miR-129 in colorecal cancerR01CA197098 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI JU, JINGFANG · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA197098
6 · The paper itself

Abstract

Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC.

Indexed as

BiomarkersChemotherapyGemcitabinemiRNAPancreatic ductal adenocarcinomaPrognosisResistance

Identifiers

PMID29942514
PMCPMC5963153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.